Background: Thalidomide, a previously banned sedative drug, was rediscovered as an immunomodulator. Multiple studies demonstrated thalidomide as an experimental treatment for refractory Crohn disease. However, the level of evidence has been limited by the overall inconsistent results. With meta-analysis, we aim to assess the effect of thalidomide and its derivative lenalidomide on refractory Crohn disease [...]